These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 6825126)

  • 1. Action of (S)-10-hydroxycamptothecin on P388 leukemia and distribution of the drug in mice.
    Creasey WA; Richards M; Gil D; Tsou KC
    Cancer Treat Rep; 1983 Feb; 67(2):179-82. PubMed ID: 6825126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo.
    Tsuruo T; Matsuzaki T; Matsushita M; Saito H; Yokokura T
    Cancer Chemother Pharmacol; 1988; 21(1):71-4. PubMed ID: 3342468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11.
    Kawato Y; Aonuma M; Hirota Y; Kuga H; Sato K
    Cancer Res; 1991 Aug; 51(16):4187-91. PubMed ID: 1651156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor effect of (S)-10-hydroxycamptothecin on mouse hepatoma BW7756 and its possible mode of action.
    Tsou KC; Xu B; Miller EE; Lo KW
    Anticancer Res; 1981; 1(2):115-9. PubMed ID: 7347154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse.
    Kaneda N; Nagata H; Furuta T; Yokokura T
    Cancer Res; 1990 Mar; 50(6):1715-20. PubMed ID: 2306725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuation of cytogenetic effects by erythropoietin in human lymphocytes in vitro and P388 ascites tumor cells in vivo treated with irinotecan (CPT-11).
    Digkas E; Kareli D; Chrisafi S; Passadaki T; Mantadakis E; Hatzimichail A; Vargemezis V; Lialiaris T
    Food Chem Toxicol; 2010 Jan; 48(1):242-9. PubMed ID: 19819285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of bouvardin (NSC 259968) on the growth characteristics an nucleic acids and protein syntheses profiles of P388 leukemia cells.
    Chitnis MP; Alate AD; Menon RS
    Chemotherapy; 1981; 27(2):126-30. PubMed ID: 7471902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity and mechanism of action of the novel marine natural products mycalamide-A and -B and onnamide.
    Burres NS; Clement JJ
    Cancer Res; 1989 Jun; 49(11):2935-40. PubMed ID: 2720652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
    Goldenberg GJ; Wang H; Blair GW
    Cancer Res; 1986 Jun; 46(6):2978-83. PubMed ID: 3698020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid-complexed camptothecin: formulation and initial biodistribution and antitumor activity studies.
    Sugarman SM; Zou Y; Wasan K; Poirot K; Kumi R; Reddy S; Perez-Soler R
    Cancer Chemother Pharmacol; 1996; 37(6):531-8. PubMed ID: 8612306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of nucleic acid synthesis in P-388 lymphocytic leukemia tumor cells by helenalin and bis(helenalinyl)malonate in vivo.
    Williams WL; Hall IH; Grippo AA; Oswald CB; Lee KH; Holbrook DJ; Chaney SG
    J Pharm Sci; 1988 Feb; 77(2):178-84. PubMed ID: 2896234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of macromolecular synthesis in P388 mouse leukemia ascites cells by bouvardin (NSC 259968).
    Chitnis M; Menon R; Adwankar M; Satyamoorthy K
    Tumori; 1985 Jun; 71(3):261-6. PubMed ID: 4024280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of resistance of a variant of P388 leukemia to L-(alpha S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
    Jayaram HN; Ardalan B; Deas M; Johnson RK
    Cancer Res; 1985 Jan; 45(1):207-12. PubMed ID: 2578092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Mechanisms of the antitumor action of spirobromine in mice with leukemia P-388].
    Sokolova IS; Riabokon' NA; Chernov VA; Gorbacheva LB
    Izv Akad Nauk SSSR Biol; 1989; (5):660-5. PubMed ID: 2584530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response of transplantable tumors in mice and of macromolecular synthesis to 17 beta-acetamido-3-aza-A-homo-4 alpha-androsten-4-one.
    Athanasiou C; Catsoulacos P; Papageorgiou A; Athanasiou K
    Cancer Invest; 1987; 5(4):301-7. PubMed ID: 3664333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1-beta-D-arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of in vivo murine tumor cell response.
    Riva CM; Rustum YM
    Cancer Res; 1985 Dec; 45(12 Pt 1):6244-9. PubMed ID: 2998596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.
    Eng WK; McCabe FL; Tan KB; Mattern MR; Hofmann GA; Woessner RD; Hertzberg RP; Johnson RK
    Mol Pharmacol; 1990 Oct; 38(4):471-80. PubMed ID: 2172765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo antitumoral activity of free, and encapsulated taxol.
    Bartoli MH; Boitard M; Fessi H; Beriel H; Devissaguet JP; Picot F; Puisieux F
    J Microencapsul; 1990; 7(2):191-7. PubMed ID: 1970357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New substances with cytotoxic and antitumor effects. IV. In vitro effect of some veratrum alkaloids and their derivatives on leukemia P388 cells.
    Fuska J; Fusková A; Vassová A; Votický Z
    Neoplasma; 1981; 28(6):709-14. PubMed ID: 7339499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity and nucleic acid binding properties of dercitin, a new acridine alkaloid isolated from a marine Dercitus species sponge.
    Burres NS; Sazesh S; Gunawardana GP; Clement JJ
    Cancer Res; 1989 Oct; 49(19):5267-74. PubMed ID: 2548717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.